Red Orbit (Free subscription) | 18/06/2008
Invivodata has announced that its DiaryPRO field-based ePRO system was used to capture primary efficacy endpoint data in the recently unblinded Phase III study of Pollinex Quattro, a vaccine being developed by Allergy Therapeutics to treat the symptoms of seasonal allergic rhinoconjunctivitis.
Red Orbit (Free subscription) | 15/05/2008
Allergy Therapeutics has announced positive results from its Pollinex Quattro Grass Phase III study, G301, a controlled allergy vaccine study.
Fiercebiotech (Free subscription) | 15/05/2008
Shares of the UK's Allergy Therapeutics surged on the news that its experimental hay fever vaccine--Pollinex Quattro--demonstrated positive results in a crucial Phase III study, which they say Read more...
Financial Time (Free subscription) | 15/05/2008
Shares in Allergy Therapeutics rose more than 20 per cent after it said it planned to file with European regulators early next year for an allergy vaccine following...
Financial Time (Free subscription) | 18/03/2008
Shares in Allergy Therapeutics fell 14 per cent yesterday, partly on the back of investor disappointment that US regulatory delays to the company's experimental...
